Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament for treating maternal-fetal ABO incompatibility

An ABO blood type and drug technology, which can be used in drug combinations, pharmaceutical formulations, plant raw materials, etc., and can solve problems such as limited effect and poor effect.

Inactive Publication Date: 2010-06-23
陈颖异
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the standard treatment of Western medicine for mother-fetal blood group incompatibility is luminal, dexamethasone and vitamins, but the effect is limited; therefore, Chinese medicine treatment has become the focus of domestic and foreign experts. Pregnancy, heat-clearing and detoxifying, promoting blood circulation and removing blood stasis, invigorating the spleen, nourishing the liver and kidney, the most representative prescriptions are Yinchenhao Decoction Modified, Tianshoutai Pill, Huanglian Jiedu Decoction, Danzhi Xiaoyao Powder, Danggui Shaoyao Powder, etc., but these Prescription is not effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for treating maternal-fetal ABO incompatibility
  • Medicament for treating maternal-fetal ABO incompatibility

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] The preparation method of the formulation of the present invention into granules will be described in detail below.

[0016] First describe the preparation method of above-mentioned first formula:

[0017] (1) Weigh 200 kg of lotus pod, 160 kg of rhubarb, 400 kg of astragalus, 400 kg of capillary, 160 kg of fried gardenia, 400 kg of Eucommia, 160 kg of wood fragrance, 300 kg of Atractylodes macrocephala, 400 kg of agrimony, Dan bark 160 kg, 160 kg ramie root, 80 kg licorice; spare;

[0018] (2) Soak the weighed woody incense in drinking water at 40°C±5°C for more than 6 hours in advance, and set aside;

[0019] (3) Add the weighed lotus pod, rhubarb, astragalus, capillary, fried gardenia, eucommia, Atractylodes macrocephala, agrimony, paeonol, ramie root, and licorice to 10 times the weight of the total weight of the above raw materials, and carry out For the first decoction, the decoction time is about 2 hours, the decoction liquid is separated for later use, and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicament for treating maternal-fetal ABO incompatibility, which is characterized by being prepared from the following components in portion: 10 to 12 portions of lotus seed pot; 6 to 10 portions of prepared rhubarb; 15 to 30 portions of raidx astragali; 15 to 30 portions of virgate wormwood herb; 6 to 10 portions of stir-fried gardenia; 15 to 30 portions of eucommia bark; 6 to 10 portions of costustoot; 12 to 20 portions of largehead atractylodes rhizome; 15 to 30 portions of hairyvein agrimonia herb and bud; 6 to 10 portions of cortex moutan; 6 to 10 portions of ramie root; and 3 to 5 portions of liquoric root. The administration of the medicament is used for treating the patient with the disease of maternal-fetal ABO incompatibility, preventing generation of hemolytic disease of the newborn, preventing fetal death, reducing the generation of netonatal hyperbilirubinemia and improving the quality of newborns.

Description

technical field [0001] The invention relates to a medicine for mainly treating neonatal hemolytic disease and hyperbilirubinemia, which belongs to the field of traditional Chinese medicine. Background technique [0002] Maternal-fetal blood type incompatibility refers to the same-family blood type immune disease caused by blood type incompatibility between pregnant women and fetuses. It occurs during the fetal period and early neonatal period. It is an important cause of neonatal hemolytic disease, which can easily cause neonatal hemolytic anemia, Heart failure, edema. ABO blood group incompatibility is the main cause of hemolytic disease of newborns in my country, accounting for 96%. Clinically, 99% of ABO blood group incompatibility occurs in pregnant women with O blood type. In recent years, the number of ABO blood group incompatibility is increasing day by day. With the popularization of eugenics knowledge, mother-child blood group incompatibility has attracted more a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/744A61K36/9064A61K36/9068A61P37/02A61P1/16
Inventor 陈颖异
Owner 陈颖异
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com